540 related articles for article (PubMed ID: 7679609)
1. Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells.
Mizutani Y; Bonavida B; Nio Y; Yoshida O
Cancer; 1993 Feb; 71(4):1313-21. PubMed ID: 7679609
[TBL] [Abstract][Full Text] [Related]
2. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
3. In vitro enhancement of natural killer cell activity by BCG and the antagonistic inhibition of the susceptibility of K562 cells to lysis by peripheral blood lymphocytes in patients with urinary bladder tumor.
Mizutani Y; Yoshida O
Int J Urol; 1994 Mar; 1(1):49-56. PubMed ID: 7627838
[TBL] [Abstract][Full Text] [Related]
4. Modulation by cis-diamminedichloroplatinum (II) of the susceptibilities of human T24 lined and freshly separated autologous urinary bladder transitional carcinoma cells to peripheral blood lymphocytes and lymphokine activated killer cells.
Mizutani Y; Nio Y; Yoshida O
J Urol; 1992 Feb; 147(2):505-10. PubMed ID: 1732632
[TBL] [Abstract][Full Text] [Related]
5. Enhanced susceptibility of c-myc antisense oligonucleotide-treated human renal cell carcinoma cells to lysis by peripheral blood lymphocytes.
Mizutani Y; Bonavida B; Fukumoto M; Yoshida O
J Immunother Emphasis Tumor Immunol; 1995 Feb; 17(2):78-87. PubMed ID: 7647959
[TBL] [Abstract][Full Text] [Related]
6. Natural cytotoxicity of human blood lymphocytes and monocytes and their cytotoxic factors: effect of interferon on target cell susceptibility.
Uchida A; Vánky F; Klein E
J Natl Cancer Inst; 1985 Nov; 75(5):849-57. PubMed ID: 2414505
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo activated memory T-lymphocytes as adoptive cellular therapy of human soft-tissue sarcoma targets with potentiation by cis-diamminedichloroplatinum(II).
Gold JE; Masters TR; Bloom ND; Shafir MK; Klein MJ; Kenan S; Osband ME
J Surg Oncol; 1995 Apr; 58(4):212-21. PubMed ID: 7723363
[TBL] [Abstract][Full Text] [Related]
8. Natural cytotoxicity of human blood monocytes and natural killer cells and their cytotoxic factors: discriminating effects of actinomycin D.
Uchida A; Klein E
Int J Cancer; 1985 May; 35(5):691-9. PubMed ID: 3997288
[TBL] [Abstract][Full Text] [Related]
9. Adriamycin-mediated potentiation of cytotoxicity against freshly isolated bladder cancer cells by autologous non-activated peripheral blood lymphocytes and tumor infiltrating lymphocytes.
Mizutani Y; Yoshida O; Miki T
J Urol; 1999 Dec; 162(6):2170-5. PubMed ID: 10569614
[TBL] [Abstract][Full Text] [Related]
10. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
Grimm EA; Mazumder A; Zhang HZ; Rosenberg SA
J Exp Med; 1982 Jun; 155(6):1823-41. PubMed ID: 6176669
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin treatment renders tumor cells more susceptible to attack by lymphokine-activated killer cells.
Yamaue H; Tanimura H; Noguchi K; Iwahashi M; Tsunoda T; Tani M; Tamai M; Hotta T; Mizobata S; Arii K
J Clin Lab Immunol; 1991 Aug; 35(4):165-70. PubMed ID: 1668852
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms involved in NK resistance induced by interferon-gamma.
Ramirez R; Solana R; Carracedo J; Alonso MC; Peña J
Cell Immunol; 1992 Mar; 140(1):248-56. PubMed ID: 1739986
[TBL] [Abstract][Full Text] [Related]
13. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effects of phorbol ester and interferon-alpha: target cell class I HLA antigen expression and resistance to natural killer and lymphokine-activated killer cell-mediated cytolysis.
Migita K; Eguchi K; Akiguchi I; Ida H; Kawakami A; Ueki Y; Kurata A; Fukuda T; Nagataki S
Cell Immunol; 1991 May; 134(2):325-35. PubMed ID: 2021973
[TBL] [Abstract][Full Text] [Related]
15. Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells.
Komatsu F; Kajiwara M
Oncol Res; 1998; 10(10):483-9. PubMed ID: 10338151
[TBL] [Abstract][Full Text] [Related]
16. The heterogeneity of target recognition by lymphokine-activated killer precursor cells.
Ibayashi Y; Gray JD; Golub SH; Daibo M; Yamaki T; Kawahara T; Kubota T; Hashi K
Jpn J Cancer Res; 1990 Sep; 81(9):927-35. PubMed ID: 2121694
[TBL] [Abstract][Full Text] [Related]
17. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.
Grimm EA; Ramsey KM; Mazumder A; Wilson DJ; Djeu JY; Rosenberg SA
J Exp Med; 1983 Mar; 157(3):884-97. PubMed ID: 6601174
[TBL] [Abstract][Full Text] [Related]
18. Reduction of susceptibility to NK lysis in cisplatin-resistant K562 cell lines.
Dedoussis G; Menounos P; Papadopoulos N; Gounaris A; Karameris A
Anticancer Res; 1998; 18(4C):3081-5. PubMed ID: 9713514
[TBL] [Abstract][Full Text] [Related]
19. Target cell membrane modification and susceptibility to lymphokine-activated killer cell-mediated lysis. II. Sodium periodate has a differential effect on the lysis of human and murine tumor cells.
Midis GP; Gupta VK; Fabian DF; Lefor AT
J Surg Res; 1994 Feb; 56(2):146-54. PubMed ID: 8121171
[TBL] [Abstract][Full Text] [Related]
20. Interferon-gamma-treated K562 target cells distinguish functional NK cells from lymphokine-activated killer (LAK) cells.
Powell J; Stone J; Chan WC; Yang ZD; Leatherbury A; Sell KW; Wiktor-Jedrzejczak W; Ahmed-Ansari A
Cell Immunol; 1989 Feb; 118(2):250-64. PubMed ID: 2491960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
